Human immunodeficiency virus-related non-Hodgkin's lymphoma

Haematologica

Volumn 93, Issue 8, 2008, Pages 1129-1132

  Ribera, Josep Maria ^a   Navarro, José Tomás ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; HYDROXYDAUNORUBICIN; INDINAVIR; PREDNISONE; RITUXIMAB; STAVUDINE; TENOFOVIR; VINCRISTINE; VINCRISTINE SULFATE; ZALCITABINE; ZIDOVUDINE;

B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD TOXICITY; BRAIN TOXICITY; BURKITT LYMPHOMA; CLINICAL FEATURE; CLINICAL TRIAL; EDITORIAL; GENE MUTATION; GERMINAL CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOGENESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; NEPHROTOXICITY; PATHOLOGY; PROGNOSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; GENE REARRANGEMENT; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE DEPLETION; LYMPHOMA, NON-HODGKIN;

EID: 48749085150     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13519     Document Type: Editorial

References (24)

1. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA; HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007;99:962-72.
2. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, et al. Non-Hodgkin's lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008;22:301-6.
3. Patel P, Hanson DL, Sulllivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence and types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728-36.
4. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in United States. Int J Cancer 2008;123:187-94.
5. Capello D, Martín M, Gloghini A, Cerri M, Rasi S, Deambrogi C, et al. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica 2008;93:1178-85.
6. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005;130:662-70.
7. JT Navarro, F Vall-Llovera, JL Mate, M Morgades, E Feliu, JM Ribera. Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiveing HAART. Haematologica 2008;93:149-50.
8. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Châtelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-44.
9. Vaccher E, Spina M, Genaro G, Talamini R, Nasti G. Concomitant cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin's lymphoma. Cancer 2001;91:155-63.
10. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired inmmunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-9.
11. Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine, and prednisone (CHOP), and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving CHOP. Haematologica 2005;90:703-5.
12. Spina M, Carbone A, Vaccher E, Gloghini A, Talamini R, Cinelli R, et al. Outcome of patients with non-Hodgkin lymphoma with or without human immunodeficiency virus infection. Clin Infect Dis 2004;38:142-4.
13. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. Prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005;143:265-73.
14. Bower M, Stebbing J Tuthill M, Campbell V, Krell J, Holmes P, et al. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 2008;111:3921-2.
15. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active antiretroviral therapy (HAART) on response to treatment and survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. Br J Haematol 2001;112:909-15.
16. Wang ES, Straus DJ, Teruya-Feldstein J, Qin J, Portlock C, Moskowitz C, et al. Intensive chemotherapy with cyclophosphamide, doxorubicine, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98:1196-205.
17. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007;110:2846-54.
18. Oriol A, Ribera JM, Esteve J, Sanz MA, Brunet S, Garcia-Boyero R, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003;88:445-53.
19. Boue F, Gabarre J, Gisselbrecht Ch, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-8.
20. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411-9.
21. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891-7.
22. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma. AIDS Malignancies Consortium Trial 010. Blood 2005;106:1538-43.
23. Oriol A, Ribera JM, Bergua J, Giménez-Mesa E, Grande C, Esteve J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt's lymphoma: comparison of results in human immunodeficiency virus-infected and non-infected patients. Cancer 2008;113-117-25.
24. Wagner-Johnston ND, Ambinder RF. Blood and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol 2008;20:201-5.